Over 400 million people have an inherited condition called glucose-6-phosphate dehydrogenase deficiency.

We could find no reference to caution in people at risk of glucose-6-phosphate dehydrogenase deficiency.

Dangerous levels of methemoglobinemia only occur in patients with glucose-6-phosphate dehydrogenase deficiency.

We present a case illustrating the particular caution necessary in subjects at risk of glucose-6-phosphate dehydrogenase deficiency.

In our patient it seems probable that the low concentrations reflected the glucose-6-phosphate dehydrogenase deficiency.

A common genetic abnormality in Africans, known as glucose-6-phosphate dehydrogenase deficiency, appears to increase the risk.

Isobutyl nitrite is poisonous to people with glucose-6-phosphate dehydrogenase deficiency.

High dose ascorbic acid can cause haemolysis in glucose-6-phosphate dehydrogenase deficiency.

Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis.

In addition, people with glucose-6-phosphate dehydrogenase deficiency may experience acute hemolysis, or dissolution of blood cells, while taking this drug.

It is important to screen people at risk of glucose-6-phosphate dehydrogenase deficiency for this disorder before starting high dose ascorbic acid.

High-dose vitamin E does not decrease the rate of chronic hemolysis in glucose-6-phosphate dehydrogenase deficiency.

Exposure to naphthalene mothballs can cause haemolysis (anemia) in people with Glucose-6-phosphate dehydrogenase deficiency.

Glucose-6-phosphate dehydrogenase deficiency.

Glucose-6-phosphate dehydrogenase deficiency must be excluded before any use of primaquine because of the risk for severe hemolytic anemia.

Phenazopyridine should be avoided by people with glucose-6-phosphate dehydrogenase deficiency, because it can cause hemolysis (destruction of red blood cells) due to oxidative stress.

Glucose-6-phosphate dehydrogenase deficiency (sometimes also called G6PD deficiency, or favism) is a hereditary disease.

Defective red cell metabolism (as in glucose-6-phosphate dehydrogenase deficiency and pyruvate kinase deficiency)

For example the widespread use of 8-aminoquinolones in areas where Glucose-6-phosphate dehydrogenase deficiency is common carries the risk of precipitating episodes of haemolysis.

Primaquine should not be administered to anyone with glucose-6-phosphate dehydrogenase deficiency because there can be a severe reaction with hemolytic anemia.

Some hemoglobinopathies (and also related diseases like glucose-6-phosphate dehydrogenase deficiency) seem to have given an evolutionary benefit, especially to heterozygotes, in areas where malaria is endemic.

Similarly, patients with Glucose-6-phosphate dehydrogenase deficiency may have impaired production of another co-factor, NADPH.

Priapism may also be associated with glucose-6-phosphate dehydrogenase deficiency, which leads to decreased NADPH levels.

Nitrofurantoin is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency because of risk of intravascular hemolysis resulting in anemia.

Henna is known to be dangerous to people with glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency), which is more common in males than females.